Leukemia Exam Review

Essential Components of Blood

• Red Blood Cells (Erythrocytes):

  • Function: Transport oxygen from the lungs to tissues and carbon dioxide back to the lungs.

  • Key Component: Contain hemoglobin, which is crucial for gas exchange.

• White Blood Cells (Leukocytes):

  • Function: Form the body's primary defense mechanism against infection, actively identifying and destroying harmful bacteria, viruses, and abnormal cells.

• Platelets (Thrombocytes):

  • Composition: Small cell fragments.

  • Function: Crucial for hemostasis (the process of stopping bleeding), forming clots to prevent blood loss, and initiating the process of tissue repair.

Understanding Leukemia: The Disease

• Definition: Leukemia is a type of cancer that originates in the bone marrow.

• Pathology: It is characterized by the overproduction of immature white blood cells, commonly referred to as blast cells.

• Affected Tissues: Primarily impacts the bone marrow, the blood-forming tissue within the body.

• Abnormal Cell Production: Involves a significant overproduction of these immature white blood cells.

• Blast Cell Accumulation: The accumulation of these immature cells leads to them crowding out and inhibiting the production and function of healthy blood cells.

Consequences of Blast Cell Overproduction and Crowding

• Decreased Red Blood Cells (RBCs):

  • Clinical Manifestations: Patients often experience chronic fatigue and exhibit signs of poor tissue perfusion due to reduced oxygen-carrying capacity.

• Thrombocytopenia (Decreased Platelets):

  • Clinical Manifestations: Leads to an increased risk for bleeding, manifesting as frequent nosebleeds, easy bruising, and prolonged bleeding from minor injuries.

• Decreased Healthy White Blood Cells (WBCs):

  • Clinical Manifestations: Results in a compromised immune system, making patients highly susceptible to various infections.

Leukemia: Risk Factors

While the precise cause of leukemia is frequently unknown, several factors are recognized for increasing an individual's risk:

• Exposure to Chemicals & Radiation:

  • Chemicals: Prolonged exposure to certain chemicals, such as benzene (found in gasoline and cigarette smoke), is a known risk factor.

  • Radiation: High doses of radiation exposure can significantly elevate the risk of developing various types of leukemia.

• Previous Cancer Treatment:

  • Individuals who have previously undergone chemotherapy or radiation therapy for other cancers may have an increased risk of developing secondary leukemia years after their initial treatment.

• Genetic Syndromes:

  • Certain inherited genetic disorders are strongly associated with a higher likelihood of developing leukemia. Examples include Down syndrome, Fanconi anemia, and Bloom syndrome.

• Smoking:

  • Cigarette smoking is a significant risk factor for developing acute myeloid leukemia (AML) due to the inhalation of various harmful carcinogens.

• Family History:

  • A family history of leukemia or other blood cancers can suggest a genetic predisposition or the inheritance of specific mutations, thereby increasing an individual's risk.

• Myelodysplastic Syndrome (MDS):

  • Description: This is a group of disorders characterized by the ineffective production of blood cells within the bone marrow.

  • Significance: MDS is considered a pre-leukemic condition because it has the potential to progress to acute leukemia, particularly Acute Myeloid Leukemia (AML).

Leukemia: Signs and Symptoms

Early detection is paramount for improving treatment outcomes. Key warning signs include:

• General Manifestations:

  • Persistent Fatigue & Weakness: Unexplained exhaustion that persists despite adequate rest, accompanied by generalized weakness.

  • Unintentional Weight Loss: Significant weight loss without conscious effort.

  • Easy Bruising/Bleeding: Frequent episodes of nosebleeds and the appearance of bruises from even minor impacts.

  • Constipation: Commonly experienced due to factors like decreased physical activity, certain medications, and dehydration.

• Immune System Indicators:

  • Recurrent Infections: Frequent fevers and prolonged recovery periods from illnesses, indicative of a weakened immune response.

• Pain and Discomfort:

  • Bone/Joint Pain: Persistent discomfort, which is particularly relevant and concerning in growing children.

• Cardiopulmonary Symptoms:

  • Respiratory Issues: Manifesting as shortness of breath, an increased respiratory rate ($RR$), and tachycardia (a rapid heart rate).

• Neurological Changes:

  • Neurological Symptoms: May include mental confusion, recurrent headaches, and noticeable changes in personality.

Leukemia: Diagnosis

The diagnostic process for leukemia involves several specialized tests to confirm the cancer's presence and determine its specific type:

• 1. Initial Blood Tests:

  • Complete Blood Counts (CBC): Reveals critical abnormalities such as excessively high or low white blood cell counts, decreased red blood cells, and low platelet levels.

  • Blood Smears: Involves microscopic examination of blood cells to assess their morphology (shape and structure), which can identify immature or abnormal cells.

• 2. Bone Marrow Biopsy:

  • Procedure: Samples of bone marrow are typically extracted from the hip bone (iliac crest) or, less commonly, the sternum.

  • Analysis: These samples are analyzed to evaluate the bone marrow's composition, identify the presence of blast cells, and determine their percentage within the marrow. This test is crucial for confirming the diagnosis.

• 3. Lumbar Puncture (Spinal Tap):

  • Procedure: Analysis of cerebrospinal fluid ($CSF$) is performed.

  • Purpose: This test determines whether leukemia cells have disseminated to the central nervous system ($CNS$), a critical assessment, especially in cases of acute leukemias.

• Importance: Early and accurate diagnosis is vital for successful treatment. Most patients require a combination of multiple diagnostic tests to confirm the diagnosis and establish the most effective therapeutic approach.

Acute Myeloid Leukemia (AML)

• Progression: AML is considered the most aggressive form of leukemia, characterized by rapid progression.

  • Without treatment, the median survival rate is a mere $2-3$ months.

• Affected Cells: It primarily affects myeloid stem cells within the bone marrow.

• Demographic Patterns:

  • AML predominantly affects older adults, with a median age of diagnosis around $68$ years.

  • Its incidence significantly increases with age.

  • It accounts for approximately $80\%$ of all acute leukemias in the adult population.

• Treatment Approach: The treatment strategy is highly individualized, depending on the patient's age, overall health status, and the presence of specific genetic mutations.

  • The standard of care involves intensive induction chemotherapy followed by consolidation therapy.

  • Allogeneic stem cell transplantation offers curative potential for eligible patients.

Acute Lymphocytic Leukemia (ALL)

• Disease Progression: ALL is characterized by the rapid overproduction of immature lymphocytes (known as lymphoblasts), which quickly crowd out healthy blood cells.

  • From onset, the disease can progress to a life-threatening stage within a matter of weeks.

• Population Affected:

  • Children: It is the most common childhood leukemia, accounting for $80\%$ of all pediatric leukemia cases.

  • Adults: While it can also affect adults, the prognosis tends to be significantly worse after the age of $30$.

• Treatment Protocols: Treatment typically spans $2-3$ years and involves a rigorous regimen including:

  • Intensive multi-drug induction phase.

  • Consolidation phase.

  • Maintenance phases.

• Outcomes:

  • Pediatric ALL: Boasts remarkable cure rates, reaching up to $90\%$.

  • Adult ALL: Outcomes for adults remain more challenging, with long-term survival rates ranging from $30-40\%$

Chronic Myelogenous Leukemia (CML)

• Disease Progression: CML has a slow and often insidious onset, typically presenting in distinct phases:

  • Chronic Phase: A stable phase where most patients are diagnosed during routine blood tests.

  • Accelerated Phase.

  • Blast Crisis Phase: An acute phase, resembling acute leukemia.

• Molecular Signature: CML is uniquely defined by the presence of the Philadelphia chromosome ($BCR-ABL$ fusion gene).

  • Found in over $95\%$ of cases.

  • This genetic abnormality results from a reciprocal translocation between chromosome $9$ and chromosome $22$.

  • The translocation creates an abnormal tyrosine kinase protein, which drives uncontrolled cell growth.

• Treatment: The introduction of tyrosine kinase inhibitors (TKIs), such as imatinib, has revolutionized CML treatment.

  • TKIs specifically target the abnormal $BCR-ABL$ protein, inhibiting its activity.

• Outcomes: With appropriate TKI therapy, $5$-year survival rates now exceed $90\%$, transforming CML from a fatal disease into a manageable chronic condition.

Chronic Lymphocytic Leukemia (CLL)

• Disease Progression: CLL is the slowest-growing type of leukemia.

  • It is characterized by the accumulation of small, mature-appearing lymphocytes in the blood, bone marrow, and lymphoid tissues.

• Asymptomatic Period: Many patients remain entirely asymptomatic for years, often managed with a